ImmunoGen shares plunge premarket after failure of breast cancer trial

ImmunoGen, the maker of breast cancer drug Kadcyla, saw it's shares drop be nearly half in pre-market trading today after a late-stage trial failed to show it provided significant benefits. The Waltham biotech company's partner on the drug, Swiss drug giant Roche, reported disappointing results from a late-stage trial of the drug early this morning. The goal of the trial of 1,095 breast cancer patients was to make Kadcyla available to newly-diagnosed patients with a genetic mutation known as HER2,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news